Autolus

Autolus, a clinical-stage biopharmaceutical company, is developing next-generation programmed T-cell therapies for cancer treatment. The company utilizes a broad suite of proprietary and modular T-cell programming technologies to design precise, targeted, controllable, and highly active T-cell therapies aimed at better recognizing cancer cells, breaking down their defense mechanisms, and eliminating these cells.